Tammie C. Yeh

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.5kcitations59works9.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(17), Multiple Myeloma Research and Treatments(15), Chronic Myeloid Leukemia Treatments(14), Acute Lymphoblastic Leukemia research(11), Chronic Lymphocytic Leukemia Research(11)

Publications59 total

ALL-636: Ponatinib Monotherapy Following Combination With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL: Phase 3 PhALLCON Post Hoc Subgroup Analysis
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CML-641 Efficacy, Safety, and End-of-Treatment Mutational Results in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): 5-Year Follow-Up of the Phase 2 OPTIC Study
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-636 Ponatinib Monotherapy Following Combination With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL: Phase 3 PhALLCON Post Hoc Subgroup Analysis
Clinical Lymphoma Myeloma & Leukemia·2025
CML-641: Efficacy, Safety, and End-of-Treatment Mutational Results in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): 5-Year Follow-Up of the Phase 2 OPTIC Study
Clinical Lymphoma Myeloma & Leukemia·2025
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2024· 4 cited
Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
Blood·2024Open Access
5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
Blood·2024· 3 citedOpen Access
ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Clinical Lymphoma Myeloma & Leukemia·2024
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
JAMA·2024· 91 citedOpen Access
Abstract 5184: Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine +/- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations
Cancer Research·2024
Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Blood·2023· 2 cited
Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2023
ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2023
S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
HemaSphere·2023· 3 citedOpen Access
Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Maureen M. Hattersley(13), Austin Dulak(13), Philip Petteruti(13), Greg O’Connor(13), Huawei Chen(13), Kevin M. Koch(9), Garrett W. Rhyasen(9), Wenxian Wang(9), Ian L. Dale(9), Scott Boiko(9), Tony Cheung(9), Shenghua Wen(9), Lillian Castriotta(9), Larry Bao(9), Miika Ahdesmäki(9), Alfred A. Rabow(9), Jonathan R. Dry(9), Corinne Reimer(9), Paul D. Lyne(9), Gordon B. Mills(9)